Introduction
Oxidative stress (O.S.) is involved in the pathogenesis of Rett syndrome (RTT) (1), a severe neurological disease affecting about 1 female newborn in 10,000 and caused in up to 95% by sporadic loss-of-function mutations in the X-linked methyl-CpG binding protein 2 (MeCP2) gene, and for which no definitive cure exists to date. Affected girls develop complex neurological symptoms with age, and the classical form of the disease (about 76% of all forms) is didactically subdivided into stages from I to IV. Cumulating evidence strongly indicates that RTT is a multisystemic disease not confined to the central nervous system but also affecting muscles (2), bone (3), lung (4) , and heart (5). The neurobiological changes in the RTT brain are likely to be complex and there is increasing evidence that MeCP2 is an important regulator of neuronal plasticity and that synaptopathy is a major component of the Rett phenotype, with recent data supporting the concept that progressive functional synaptic impairment is a key feature in the RTT brain (6) . Anatomical studies have shown changes in synaptic connectivity and neuronal structure (7) (8) (9) (10) (11) whilst at the network level there are changes in network excitability (12, 13) . Although lack of functional MeCP2 results in a nervous system primed to malfunction at a critical point during postnatal brain development, functions can be restored to a large degree once MeCP2 expression is restored to wild-type levels, raising expectations about the possibility of therapeutic intervention (14) .
To date, little is known regarding brain white matter damage in RTT although a recent neuroimaging study indicates the importance of a white matter abnormality related to more severe language compromise. However, in the lack of histologic data, it is difficult to conclude about the exact mechanism of the fractional anisotropy decrease observed in this patient population. Past studies have suggested axonal involvement to explain fractional anisotropy reduction, but loss of myelin has not been shown to be a contributing factor (15) .
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Patients and Methods
Subjects
The study included a total of 91 RTT female patients with different clinical diagnoses: typical RTT (n=70, mean age: 11.9 ± 8.0 years; range 1.0-33; demonstrated MeCP2 mutation), preserved speech variant (PSV) (n=11, mean age: 18.5 ± 6.1 years; range: 10-30; demonstrated MeCP2 mutation), and early seizure variant (ESV) (n=10, mean age: 9.0 ± 3.5 years; range: 5-13; demonstrated CDKL5 mutation). RTT diagnoses and inclusion/exclusion criteria were based on the recently revised RTT (21) .
All the patients were consecutively admitted to the Rett Syndrome National Reference Centre of the University Hospital of the Azienda Ospedaliera Universitaria Senese (AOUS). The subjects examined in this study followed a typical Mediterranean diet. The study was restricted to assessment of cases with the nine most frequently reported MeCP2 mutations (22, 23) plus large gene deletions.
Gender-matched healthy control subjects of comparable age (n=43, all females; age: 13.9 ± 6.0 years, range 1.5-32) were also included. Blood samplings in the control group were carried out during routine health checks, sports, or blood donations.
The study was conducted with the approval of the Institutional Review Board and written informed consents were obtained from either the parents or the legal tutors of the enrolled patients or directly from healthy adults.
RTT clinical severity was assessed using the clinical severity score (CSS), a validated clinical rating specifically designed for RTT (25) , based on 13 individual, ordinal categories measuring clinical features common in RTT. All scores range from 0 to 4 or 0 to 5 with 0 representing the least severe and 4 or 5 representing the most severe finding. A series of individual clinical items of interest were also evaluated to compress the ordinal category measures into a binary measurement with 0 representing "mild" or "retained function" and 1 representing "severe" or "lost/absent function" (25) . Mild or retained functions were considered in the case of neurologic regression after 18 months of life, weight decrease < 2SD, head circumference greater than the 10 th percentile after 24 months of life, sitting maintained, independent walking, hands use at least partially conserved, scoliosis <20°, use of at least single words, maintained eye contact for at least 5 seconds, presence of minimal respiratory dysfunction (<10% of the time), stereotypy onset after 36 months of life, and seizures absent or less than monthly (26) .
Blood Sampling
Blood was collected in heparinized tubes and all manipulations were carried out within 2 hours after collection. Blood samples were centrifuged at 2400 x g for 15 min at room temperature. The platelet poor plasma was saved and the buffy coat was removed by aspiration. Butylated hydroxytoluene (BHT) (90 µM) was added to plasma as an antioxidant and the samples were stored under nitrogen at -70°C until analysis.
F 2 -dihomo-IsoP syntheses
We have recently developed a new general strategy in order to rapidly access to F-, E-and DIsoprostanes, using a common keto-epoxide[3.3.0]octene intermediate 1 (20, 27) . Using this precursor, we now report the synthesis of ent-7(RS)-F 2t -dihomo-IsoP, and 17-F 2t -dihomo-IsoP (Scheme 1).
The mono-acetate intermediate 4 was obtained in 5 steps from the keto-epoxide 1 on multigram scale, after successive reductions, protection and enzymatic regioselective mono-acetylation (Scheme 2) (20, 27) . Likewise the ent-7(RS)-F 2t -dihomo-IsoP synthesis, this metabolite was obtained starting from mono acetate 4 in 9 steps, using commercially available dimethyl-2-oxo-heptylphosphonate 8 and (7-ethoxy-7-oxoheptyl)triphenyl phosphonium bromide 11, prepared in one step and 93% yield from ethyl 7-bromo heptanoate.
As described in Scheme 4, the enone 9 was obtained with 57% yield after Dess-Martin oxidation of alcohol 5 and HWE olefination with the β-ketophoshonate 8 and barium hydroxide. Enone 9 reduction was realized under Luche conditions and the corresponding 1:1 epimer mixture was subsequently protected as ethoxy ether 10 with 91% yield over two steps.
The lower chain was introduced after saponification of the acetate group, followed by oxidation, separation of the two epimers at C17, then a Wittig elongation using the previously synthesized phosphonium salt 11, NaHMDS in THF, in 64% yield after four steps. Final acid cleavage of silylated ether 12, followed by ethyl ester saponification allowed the access to 17-F 2t -dihomo-IsoP 3 with 63% yield after two steps. introduced into the gas chromatograph (Trace GC, ThermoFinnigan, San Jose, CA, USA) in the splitless mode (splitless time 2 min). Sample aliquots of (2 µl) were injected. The gas chromatograph oven was programmed from 175°C (3 min) to 270°C at a rate of 30°C/min. The temperature of the injector was 250°C; the transfer line was heated to 280°C and the ion source to 200°C. The carrier gas was ultrapure helium maintained at a constant flow of 1 ml/min. The GC column enters the ion source of the mass spectrometer. An ion trap was used as mass analyzer (PolarisQ, ThermoFinnigan). Methane was used as reagent gas for NICI at a flow of 2.0 ml/min.
The precursor ion isolation width was 1.5 Da, the multiplier was set to 1550 V, and the automatic gain control was used.
In order to rule out a potential generation of F 2 -dihomo-IsoPs by artifactual oxidation of plasma, samples from 3 RTT patients (stage IV of the disease) were incubated at 37°C for 1 h with 10 mM-2, 2' azobis (2-aminopropane) hydrochloride (AAPH), a well-known, commonly used free radical initiator (28, 29)
Data Analysis
All variables were tested for normal distribution (D'Agostino-Pearson test) and data were presented as means with 95% confidence intervals (95% C.I.) for normally distributed variables or medians means with 95% C.I. for nonnormally distributed data. Differences between groups were evaluated using independent-sample t test (continuous normally distributed data), Mann-Whitney rank sum 
Results
The The intra-assay coefficient of variability, as determined by three replicated measurements of the physiological content of F 2 -dihomo-IsoPs in biological samples, was 4.33 ± 0.86 %. Inter-assay coefficient of variability measured by comparing three samples containing specific amounts of authentic (i.e., synthetized molecules) F 2 -dihomo-IsoPs, was 4.47 ± 0.50 %. The employed method was shown to be also accurate (i.e., closeness to the actual true quantity value), i.e., 99,2%.
As a consequence, although at this stage of the work, we are not able to fully establish the recovery of the compounds through the assay, the method appears to be sufficiently accurate and precise/reproducible.
Plasma F 2 -dihomo-IsoP levels in age and gender matched healthy controls range between 0.8 and 1.2 pg/ml (mean ± SEM, 1.0 ± 0.11 pg/ml). No statistically significant correlation between age and F 2 -dihomo-IsoPs in the normal subjects was observed (r = 0.0841, P = 0.40).
Plasma F 2 -dihomo-IsoPs were increased by about 2 orders of magnitude in RTT patients in stage I of the disease (185.9 ± 68.9 pg/ml; stage I vs. controls, P < 0.0001), while these values decreased by about 2 to 3 folds higher than in controls in later stages of the natural progression of the disease (stage II: 3.75 ± 0.43 pg/ml; stage III: 2.65 ± 1.15 pg/ml; stage IV: 2.53 ± 0.54 pg/ml) (Fig. 4) .
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In a sub-sample of 26 RTT patients at different stages (I to IV), no statistically significant relationships were observed between plasma F 2 -dihomo-IsoPs levels and the concentrations of Patients with the early onset seizure variant show F 2 -dihomo-IsoPs levels comparable to those of the late typical (clinical stages II to IV of the disease) form patients, whereas patients with preserved speech variant i.e., the mildest form of RTT with somehow preserved verbal language (phrases and sentences), show levels comparable to those of healthy controls ( Table 2) .
The results of in vitro oxidation of plasma samples from RTT patients with AAPH showed a lack of significant increase in F 2 -dihomo-IsoPs levels, thus indicating that the presence of F 2 -dihomo-IsoPs in RTT plasma is not due to artifactual oxidation from plasma sources (from 3.55 ± 0.77 pg/ml to 2.85 ± 0.07 pg/ml).
Discussion
As recently described by VanRollins et coll. (18) AdA oxidation products, like F 2 -IsoPs, form four series of regioisomeric isoprostanoids including 7-, 10-, 14-, and 17-series termed 7-, 10-, 14-, and 17-dihomo-IsoPs (Fig. 5) , and show that 7-and 17-series are the most abundant.
Roberts and coll. (31) In the present study, we described the synthesis of the 7-and 17-series of F 2 -dihomo-IsoPs and investigated their potential value as biomarkers of lipid peroxidation in RTT.
In this study, for the first time increased F 2 -dihomo-IsoP levels in plasma samples from RTT patients were detected. In particular, extremely high plasma levels of these AdA oxidation products were found in RTT girls on stage I of the disease, a stage characterized by a dramatic neurologic regression that represents one of the major hallmarks of this neurologic disease.
At this stage of our research it is not possible to attribute the demonstrated changes in F 2 -dihomoIsoPs levels in RTT patients with 100% certainty to white matter oxidative damage only, considering that AdA, the source for F 2 -dihomo-IsoPs, is known to be present in several organs and tissues including the kidney and the adrenal glands from which it has been named (19) . The main message of the present work is that, although it is certainly true that in RTT both AdA and DHA undergo a non enzymatic oxidation, as compared to healthy controls, AdA, whatever the actual origin (brain white matter, adrenal gland or kidney), is the polyunsaturated fatty acid that goes through the greatest degree of oxidation in the earliest stage of the typical form of the disease. On the other hand, in order to demonstrate that the F 2 -dihomo-IsoPs changes here observed are due to brain white matter damage, the measure of F 2 -dihomo-IsoPs in a MeCP2-central nervous system by guest, on November 9, 2017 www.jlr.org
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knock-out animals would be needed in order to confirm or rather rule out our speculated origin of the F 2 -dihomo-IsoPs from the brain.
Our finding suggests that brain oxidative damage is already occurring during the first two years of the natural evolution of the disease and that this damage is also involving the peroxidation of AdA, a known component of myelin, in the primate brain. To date, there is very little information regarding the brain white matter in RTT, although a recent investigation has evidenced a significant relationship between brain white matter damage (particularly of the superior longitudinal fasciculus, one of the main association bundles connecting the external surface of temporo-parieto-occipital regions with the convexity of the frontal lobe and in part associated with phonologic speech) (34,
35) and ability to speak (15).
Our data, based on plasma F 2 -dihomo-IsoP changes in stage I RTT, would suggest a previously unrecognized role for myelin oxidative damage occurring early during the natural progression of the disease. A prior study has reported an abnormality of white matter in RTT (36) . Further supporting the concept of an early white matter damage in RTT, is the observation that some neurological signs (cognitive decline up to dementia, motor impairment, aphasia, apraxia) overlap with those of Xlinked adrenoleukodystrophy, a rare inherited disorder leading to progressive brain damage, failure of the adrenal glands and eventually death, and caused by defects in the ATP-binding cassette subfamily D member 1 transporter protein encoded by the ABCD1 gene (37) . Curiously, the ABCD1 protein is indirectly involved in the breakdown of very long-chain fatty acid (VLCFAs)
found in the diet, and lack of this protein can give rise to an over-accumulation of VLCFAs which can lead to damage to brain, adrenal glands an peripheral nervous system.
The ophthalmologic involvement, including nystagmus, is more typical for the subacute or chronic demyelinating diseases such as multiple sclerosis, and is usually absent in typical RTT (38) . Thus, a component of the symptomatologic picture at the onset for typical RTT could be related to an early brain white matter oxidation.
The process of human myelination has been recently revised by using a new brain NMR technique (i.e., quantitative myelin imaging with mcDESPOT) (39) showing that, at the mean age of neurological regression in RTT (i.e., about 12 months), myelin is already present in the cerebellum, pons, and internal capsule, splenium of the corpus callosum and optic radiations (by age of 5 months); the occipital and parietal lobes (by 5-6 months), and genu of the corpus callosum and frontal and temporal lobes after 8.3 months, thus mirroring the spatiotemporal pattern established by prior histological studies (40, 41) .
Thus, an oxidative insult during the typical window of the RTT onset (6 to 18 months) is potentially able to damage myelin and likely correspond to an increase in F 2 -dihomo-IsoPs in the blood stream.
As a corollary, an hypoxic process in the first days of life would not be able to generate an increase in F 2 -dihomo-IsoPs as the myelination process is just at the initial stages. Hence, the ideal age for a biochemical screening for typical RTT would be in between 3 and 6 months of age in girl infants with subtle neurologic abnormalities. As prior reports have evidenced an abnormal neurologic behaviour already in the first 4 months of life in girls with RTT (42, 43) .
During the RTT progression, we observed a dramatic decrease in plasma F 2 -dihomo-IsoPs although levels did not reach the normality range, thus strongly indicating that a brain white matter must be present throughout all the natural history of the disease. In the present study, an exact matching between synthesized F 2 -dihomo-IsoPs and measured isomers was found, thus indicating the precise chemical structure of the detected peak in plasma samples. These two major series (7-and 17-F 2 -dihomo-IsoPs) could became potential therapeutical targets or, at least, early indicators of the onset of the disease, even before the knowledge of gene mutation. In the near future it will be interesting to evaluate the behaviour of In RTT patients we have previously shown the coexistence of hypoxia (mild chronic hypoxia) and systemic oxidative stress (16) . The key biological concept that, under hypoxic conditions, oxidative stress (i.e., generation of the superoxide radical in the specific case) can paradoxically be generated This points strongly reinforce the general concept that hypoxia can be linked to oxidative stress and viceversa. How and when hypoxia occurs during the RTT natural history is, of course, a major issue deserving to be addressed in the near future.
In addition, our findings indicate the importance of plasma as a suitable biological fluid for detecting markers of central nervous system oxidative damage in RTT (16, 55, 56) and underline the key role of interaction between organic chemists, O.S. biochemists and clinicians toward the discovery of new markers of disease and potential targets for new interventional strategies.
In conclusion, our results indicate for the first time that quantification of F 2 -dihomo-IsoPs in plasma represents an early marker of the disease and may provide a better understanding of the pathogenic mechanisms behind the neurological regression in patients with RTT. cannot have stages but they have been matched for gender (all females) and age with patients at stages I (control subjects n= 10, mean age 1.5 years), II (control subjects n=15, mean age 5 years), III (control subjects n=20, mean age 12 years) and IV (control subjects n=25, mean age 16 years).
Plasma F 2 -dihomo-IsoPs values are presented in logarithmic scale. 
